Ledger.Open graph →

SEC Form D · Amendment · filed November 2, 2022

Elicio Therapeutics, Inc

Offering

$50.0M

Sold

$22.0M

Exemption

Rule 506(b)

Industry

Biotechnology

Location

BOSTON, MA

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (28)

Annette Matthies · Boston, MAExec Christopher Haqq · Boston, MAExec Robert Ruffolo · Boston, MADirector Daphne Karydas · Boston, MADirector Carol Ashe · Boston, MADirector Daniel Geffken · Boston, MAExec · Director Robert Connelly · Boston, MAExec · Director Julian Adams · Boston, MADirector Yekaterina Chudnovsky · Boston, MADirector Assaf Segal · Boston, MADirector Daniel Hilson · ANN ARBOR, MIDirector Mark Disiena · Wichita, KSExec Christophe Seywert · Grand Duchy of Luxembourg, LuxembourgDirector Anthony Brasher · ANN ARBOR, MIDirector Grant Begley · Wichita, KSDirector Kelly Anderson · Wichita, KSExec · Director Thomas Gardner · Wichita, KSExec Jared Champlin · Dallas, TXExec · Director Julian R. Marcu · CHELSEA, MADirector Ellen R. Reilly · CHELSEA, MAExec Thomas Hulick · Pasadena, CADirector John Dunkelberger · Eden Prairie, MNExec · Director Thomas Mallon · INCLINE VILLAGE, NVExec Antonio Salgado · Long Beach, NYExec · Director Marc Jordan · Encino, CADirector H. M. Chambers · Leeds, ALDirector Yekaterina Chudnovsky · Boston, MADirector Assaf Segal · Boston, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗